Literature DB >> 20808293

Hepatotoxic effects of therapies for tuberculosis.

Bahaa E Senousy1, Sanaa I Belal, Peter V Draganov.   

Abstract

Hepatotoxic effects attributable to antituberculosis therapy are considered unique among drug-related liver problems because almost all first-line antituberculosis medications have such adverse effects, which vary in severity according to the drug and the regimen. In addition, all regimens for the treatment of active tuberculosis include a combination of medications that must typically be administered for at least 6 months to ensure complete cure of the disease and to minimize the development of drug-resistant bacterial strains. Hepatotoxic effects are a serious problem in patients who are undergoing treatment for tuberculosis, not only because of the morbidity and mortality they directly cause, but also because the liver symptoms can necessitate interruption of therapy or affect a patient's adherence to it, which can limit the efficacy of the antitubercular regimen.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20808293     DOI: 10.1038/nrgastro.2010.134

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  166 in total

1.  Antituberculosis drugs and hepatotoxicity.

Authors:  Wing W Yew; Chi C Leung
Journal:  Am J Respir Crit Care Med       Date:  2007-04-15       Impact factor: 21.405

2.  Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic.

Authors:  C M Nolan; S V Goldberg; S E Buskin
Journal:  JAMA       Date:  1999-03-17       Impact factor: 56.272

Review 3.  Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis.

Authors:  G A Ellard
Journal:  Clin Pharmacol Ther       Date:  1976-05       Impact factor: 6.875

4.  Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis.

Authors:  Tina Papastavros; Lisa R Dolovich; Anne Holbrook; Lori Whitehead; Mark Loeb
Journal:  CMAJ       Date:  2002-07-23       Impact factor: 8.262

5.  Observations on the reduction of the renal elimination of urate in man caused by the administration of pyrazinamide.

Authors:  G A Ellard; R M Haslam
Journal:  Tubercle       Date:  1976-06

Review 6.  Influence of diet and nutritional status on drug metabolism.

Authors:  I Walter-Sack; U Klotz
Journal:  Clin Pharmacokinet       Date:  1996-07       Impact factor: 6.447

7.  Hepatotoxicity of rifampin and isoniazid. Is it all drug-induced hepatitis?

Authors:  A Kumar; P K Misra; R Mehotra; Y C Govil; G S Rana
Journal:  Am Rev Respir Dis       Date:  1991-06

8.  Single- and multiple-dose pharmacokinetics of intravenous moxifloxacin in patients with severe hepatic impairment.

Authors:  Jürgen Barth; Doris Jäger; Ralf Mundkowski; Bernd Drewelow; Tobias Welte; Olaf Burkhardt
Journal:  J Antimicrob Chemother       Date:  2008-05-30       Impact factor: 5.790

9.  A model of isoniazid-induced hepatotoxicity in rabbits.

Authors:  T C Sarich; T Zhou; S P Adams; A I Bain; R A Wall; J M Wright
Journal:  J Pharmacol Toxicol Methods       Date:  1995-10       Impact factor: 1.950

10.  Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis.

Authors: 
Journal:  Lancet       Date:  1981-01-24       Impact factor: 79.321

View more
  20 in total

1.  Answers to multiple choice questions.

Authors:  Swastik Agrawal; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2012-12

Review 2.  A guide to the management of tuberculosis in patients with chronic liver disease.

Authors:  Radha K Dhiman; Vivek A Saraswat; Harshal Rajekar; Chandrasekhar Reddy; Yogesh K Chawla
Journal:  J Clin Exp Hepatol       Date:  2012-09-21

3.  Tuberculosis in Cirrhosis - A Diagnostic and Management Conundrum.

Authors:  Saurabh Mishra; Sunil Taneja; Arka De; Valliappan Muthu; Nipun Verma; Madhumita Premkumar; Ajay Duseja; Virendra Singh
Journal:  J Clin Exp Hepatol       Date:  2021-09-10

4.  Alkaloids of Dicranostigma franchetianum (Papaveraceae) and Berberine Derivatives as a New Class of Antimycobacterial Agents.

Authors:  Viriyanata Wijaya; Ondřej Janďourek; Jana Křoustková; Kateřina Hradiská-Breiterová; Jan Korábečný; Kateřina Sobolová; Eliška Kohelová; Anna Hošťálková; Klára Konečná; Marcela Šafratová; Rudolf Vrabec; Jiří Kuneš; Lubomír Opletal; Jakub Chlebek; Lucie Cahlíková
Journal:  Biomolecules       Date:  2022-06-17

Review 5.  Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review.

Authors:  Jonathan G Stine; James H Lewis
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2015-12-25       Impact factor: 3.869

Review 6.  Antitubercular therapy in patients with cirrhosis: challenges and options.

Authors:  Naveen Kumar; Chandan Kumar Kedarisetty; Sachin Kumar; Vikas Khillan; Shiv Kumar Sarin
Journal:  World J Gastroenterol       Date:  2014-05-21       Impact factor: 5.742

7.  Compensatory Transition of Bile Acid Metabolism from Fecal Disposition of Secondary Bile Acids to Urinary Excretion of Primary Bile Acids Underlies Rifampicin-Induced Cholestasis in Beagle Dogs.

Authors:  LanLan Gui; QingLiang Wu; YiTing Hu; WuShuang Zeng; XianWen Tan; PingPing Zhu; XueJing Li; Lian Yang; Wei Jia; ChangXiao Liu; Ke Lan
Journal:  ACS Pharmacol Transl Sci       Date:  2021-03-22

8.  Dietary Intake of Vegetables and Cooking Oil Was Associated With Drug-Induced Liver Injury During Tuberculosis Treatment: A Preliminary Cohort Study.

Authors:  Jinyu Wang; Ke Xiong; Lei Xu; Chao Zhang; Shanliang Zhao; Yufeng Liu; Aiguo Ma
Journal:  Front Nutr       Date:  2021-05-24

9.  Effect of scheduled monitoring of liver function during anti-Tuberculosis treatment in a retrospective cohort in China.

Authors:  Shanshan Wu; Yinyin Xia; Xiaozhen Lv; Yuan Zhang; Shaowen Tang; Zhirong Yang; Dehua Tu; Peiyuan Deng; Shiming Cheng; Xiaomeng Wang; Yanli Yuan; Feiying Liu; Daiyu Hu; Siyan Zhan
Journal:  BMC Public Health       Date:  2012-06-19       Impact factor: 3.295

10.  Prescribing medications in patients with decompensated liver cirrhosis.

Authors:  Deepak N Amarapurkar
Journal:  Int J Hepatol       Date:  2011-08-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.